ORIGINAL ARTICLE
Ahead of Print

Prevalence and clinical application of TMPRSS2-ERG fusion in Asian prostate cancer patients: a large-sample study in Chinese people and a systematic review


1 Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433, China
2 Department of Pathology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433, China

Correspondence Address:
Xu Gao,
Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433
China
Ying-Hao Sun,
Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/aja.aja_45_19

PMID: 31210145

Fusion between the transmembrane protease serine 2 and v-ets erythroblastosis virus E26 oncogene homolog (TMPRSS2-ERG fusion) is a common genetic alteration in prostate cancer among Western populations and has been suggested as playing a role in tumorigenesis and progression of prostate cancer. However, the prevalence of TMPRSS2-ERG fusion differs among different ethnic groups, and contradictory results have been reported in Asian patients. We aim to evaluate the prevalence and significance of TMPRSS2-ERG fusion as a molecular subtyping and prognosis indicator of prostate cancer in Asians. We identified the fusion status in 669 samples from prostate biopsy and radical prostatectomy by fluorescence in situ hybridization and/or immunohistochemistry in China. We examined the association of TMPRSS2-ERG fusion with clinicopathological characteristics and biochemical recurrence by Chi-square test and Kaplan–Meier analysis. Finally, a systematic review was performed to investigate the positive rate of the fusion in Asian prostate cancer patients. McNemar's test was employed to compare the positive rates of TMPRSS2-ERG fusion detected using different methods. The positive rates of TMPRSS2-ERG fusion were 16% in our samples and 27% in Asian patients. In our samples, 9.4% and 19.3% of cases were recognized as fusion positive by fluorescence in situ hybridization and immunohistochemistry, respectively. No significant association between the fusion and clinical parameters was observed. TMPRSS2-ERG fusion is not a frequent genomic alteration among Asian prostate cancer patients and has limited significance in clinical practices in China. Besides ethnic difference, detection methods potentially influence the results showing a positive rate of TMPRSS2-ERG fusion.


[FULL TEXT] [PDF]
Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Kong DP
    -  Chen R
    -  Zhang CL
    -  Zhang W
    -  Xiao GA
    -  Wang FB
    -  Ta N
    -  Gao X
    -  Sun YH
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed319    
    PDF Downloaded27    

Recommend this journal